Global Elonva market projected to accelerate through 2035

The Business Research Company says the global Elonva market is set for strong growth through 2035 as infertility rates rise, IVF demand expands and fertility care becomes more accessible. North America led the market in 2025, while Asia-Pacific is expected to grow fastest over the forecast period.

Why it matters: - The Elonva market is tied to broader fertility treatment demand, which is rising as more people seek assisted reproductive technologies. - Growth in this market reflects higher infertility rates, expanding IVF use and a shift toward more patient-friendly ovarian stimulation protocols. - Elonva’s single-injection format may reduce treatment burden for patients who otherwise need daily hormone shots.

What happened: - The Business Research Company released its Global Elonva Market Report 2026 with a market outlook covering 2026-2035. - The report says the global Elonva market is entering a period of rapid growth. - The company identifies North America as the largest regional market in 2025. - The report names Asia-Pacific as the fastest-growing region over the forecast period.

The details: - Elonva, or corifollitropin alfa, is used in assisted reproductive technologies such as IVF. - The drug stimulates the ovaries to produce multiple follicles, supporting egg retrieval. - Elonva’s long-acting formulation allows ovarian stimulation to begin with a single injection. - The report says the market has already benefited from rising infertility, proven assisted reproductive technologies, more fertility clinics, greater use of hormonal stimulation therapies and wider awareness of reproductive health. - Future growth is expected to be supported by delayed parenthood, more IVF cycles, improved fertility drug technology, broader healthcare access in emerging markets and better reimbursement options. - Forecast developments include single-injection ovarian stimulation protocols, more IVF procedures, more patient-friendly fertility treatments, tighter control of ovarian response and greater use of long-acting gonadotropins. - The report links ovarian disorders to market growth, citing hormonal imbalances, BRCA1 and BRCA2 mutations, PCOS, autoimmune disease, toxin exposure, obesity and smoking as contributing factors. - The American Cancer Society reported 19,680 new ovarian cancer cases and 12,740 related deaths in the U.S. in 2024. - The World Health Organization said in April 2023 that about 17.5% of the global adult population, or roughly one in six people, experience infertility. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company is offering a free sample of the market report and the full Elonva market report.

Between the lines: - The report points to a market shaped less by one drug and more by a structural rise in fertility care demand. - Single-injection protocols could become more attractive as clinics look for simpler stimulation regimens and patients seek less burdensome treatment. - Faster growth in Asia-Pacific suggests the biggest upside may come from expanding access rather than from mature markets alone.

What's next: - The report expects continued expansion through 2035 as fertility care becomes more accessible and IVF volumes rise. - Market tracking will likely focus on reimbursement trends, clinic expansion and adoption of long-acting stimulation regimens. - The company’s 2026 report set also adds TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspot infographics and updated graphics and tables.